Zika Virus Replicons for Drug Discovery

EBioMedicine

Yujiao Yang¹  Jing Zou¹  Dieudonné Buh Kum¹  Xuping Xie¹  Pei-Yong Shi¹  Chao Shan¹  Johan Neyts²  Kai Dallmeier² 

[1] Department of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA;Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, University of Leuven, Leuven, Belgium;

关键词: Zika;    Drug discovery;    Replicon;    Flavivirus;   

DOI  :  10.1016/j.ebiom.2016.09.013

来源: DOAJ

【 摘 要 】

The current epidemic of Zika virus (ZIKV) has underscored the urgency to establish experimental systems for studying viral replication and pathogenesis, and countermeasure development. Here we report two ZIKV replicon systems: a luciferase replicon that can differentiate between viral translation and RNA synthesis; and a stable luciferase replicon carrying cell line that can be used to screen and characterize inhibitors of viral replication. The transient replicon was used to evaluate the effect of an NS5 polymerase mutation on viral RNA synthesis and to analyze a known ZIKV inhibitor. The replicon cell line was developed into a 96-well format for antiviral testing. Compare with virus infection-based assay, the replicon cell line allows antiviral screening without using infectious virus. Collectively, the replicon systems have provided critical tools for both basic and translational research.

【 授权许可】

Unknown